HC Wainwright Reiterates Buy Rating for Lisata Therapeutics
LSTA Stock | USD 2.65 0.04 1.53% |
About 52% of Lisata Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that some traders are interested. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
Lisata |
Lisata Therapeutics s stock had its buy rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a 15.00 price target on the stock. HC Wainwrights price objective points to a potential upside of 411.95 percent from the companys previous
Read at thelincolnianonline.com
Lisata Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lisata Therapeutics Fundamental Analysis
We analyze Lisata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Lisata Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Lisata Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lisata Therapeutics stock to make a market-neutral strategy. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with similar companies.
Peers
Lisata Therapeutics Related Equities
PTIX | Protagenic Therapeutics | 16.25 | ||||
PULM | Pulmatrix | 2.15 | ||||
ANTX | AN2 Therapeutics | 0.75 | ||||
MBRX | Moleculin Biotech | 0.54 | ||||
BPTH | Bio Path | 0.14 | ||||
XOMAO | XOMA | 0.12 | ||||
IMNN | Imunon | 2.18 | ||||
GLUE | Monte Rosa | 2.74 | ||||
RZLT | Rezolute | 3.56 | ||||
TPST | Tempest Therapeutics | 3.80 | ||||
CADL | Candel Therapeutics | 4.39 | ||||
LIXT | Lixte Biotechnology | 12.18 |
Complementary Tools for Lisata Stock analysis
When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |